Taiyo : Consolidated Financial Result Digest FY2022 Q4 (Fiscal Year Ended March 31,2022)

ENGLISH TRANSLATION OF JAPANESE-LANGUAGE DOCUMENT

This is a translation of the original Japanese-language document and is provided for convenience only. In all cases, the Japanese-language original shall take precedence.

Consolidated Financial

Result Digest FY2022 Q4

(Fiscal Year Ended March 31, 2022)

April 28, 2022

Any information incorporated in this document is not intended for suggestion of purchase or sale of equity share of the company. All the description and projection are based on the company's own analysis at the time of compilation, and their accuracy is not guaranteed. These data may be revised without prior announcement. The company will neither assume nor compensate any loss of anybody resulting from decision based on information provided here.

Our Reporting Segments

Electronic Materials

Develops, manufactures, purchases and sells chemicals for PWBs and other electronic components

Medical and Pharmaceutical

Manufactures and markets pharmaceuticals, and provides contract development and manufacturing organization (CDMO) services

Others

Energy business using natural energy, food business, fine chemicals business including dyes, pigments and other chemicals, and ICT business, etc.

FY2022 Q4 Overview

⚫ Net sales increased by 34% year on year

⚫ Operating income increased by 52% year on year

Main reasons

• • New white dry film-type solder resist, which has been mass-produced since the first quarter, has been used for Mini LED displays and sold very well

• • Strong semiconductor market resulted in record high sales of PKG Products

⚫ Net sales decreased by 4% year on year

Main reasons

• • Lower sales volume of other infectious disease-related products due to thorough countermeasures against the COVID-19 pandemic

• • Impact of production adjustments as a result of changes to production plans by contract manufacturing clients

• • Lower drug price due to the National Health Insurance (NHI) price revision of Long Listed Products

• • Higher sales volume of some products as a result of suspensions to the supply of other companies' generic drugs ⚫ Completed the succession of manufacturing and marketing approval and transfer of distribution for all four products from AstraZeneca K.K.

⚫ Acquired treasury stock

Shares acquired : 464,400 shares

Total acquisition amount : Approximately 1,500 JPY million ⚫ Support for TCFD recommendations and participation in TCFD Consortium

*1 JPY/USD exchange rate : Actual results for FY2022 3Q cumulative 111.4 JPY. Estimated value for FY2022 4Q 108.0 JPY.

120

100

Operating Income（Right axis）

Other Sales（Left axis）

Medical and Pharmaceutical Sales（Left axis）Electronic Materials Sales（Left axis）

109

97

4

25 [23%]

FY2012/3 FY2013/3 FY2014/3 FY2015/3 FY2016/3 FY2017/3 FY2018/3 FY2019/3 FY2020/3 FY2021/3 FY2022/3 FY2023/3

30

25